Agios Pharmaceuticals GAAP EPS of 16.22 beats by 7.53, revenue of 8.96M misses by 0.54M
MACKDelisted Stock | USD 11.96 0.12 1.01% |
About 50% of Merrimack Pharmaceuticals' institutional investors are presently thinking to get in. The analysis of current outlook of investing in Merrimack Pharmaceuticals suggests that some traders are interested regarding Merrimack Pharmaceuticals' prospects. Merrimack Pharmaceuticals' investing sentiment shows overall attitude of investors towards Merrimack Pharmaceuticals.
Merrimack |
Agios Pharmaceuticals beats Q3 EPS estimates by 7.53, but misses revenue expectations by 0.54M.
Read at seekingalpha.com
Merrimack Pharmaceuticals Fundamental Analysis
We analyze Merrimack Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merrimack Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merrimack Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Merrimack Pharmaceuticals is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Merrimack Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Merrimack Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Merrimack Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Merrimack Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Merrimack Pharmaceuticals Related Equities
PBYI | Puma Biotechnology | 4.95 | ||||
AGIO | Agios Pharm | 1.24 | ||||
FOLD | Amicus Therapeutics | 0.20 | ||||
CLDX | Celldex Therapeutics | 1.61 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Merrimack Stock
If you are still planning to invest in Merrimack Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Merrimack Pharmaceuticals' history and understand the potential risks before investing.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |